Oral Low-Dose Naltrexone in the Treatment of Frontal Fibrosing Alopecia and Lichen Planopilaris: An Uncontrolled Open-Label Prospective Study

This study investigated the use of low-dose naltrexone (3 mg daily) as adjunctive therapy for frontal fibrosing alopecia (FFA) and lichen planopilaris (LPP) in 26 patients over one year. Results showed a significant decrease in erythema at 12 months compared to baseline, with a mean reduction of 0.93 on a 0-3-point scale (p<0.0001). However, there were no significant changes in pruritus, burning/pain, or scalp involvement. The study suggests that low-dose naltrexone may be beneficial for treating erythema in FFA and LPP, though further research is needed due to limitations such as small sample size and concurrent medications.